These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12577958)

  • 1. [Multiple myeloma and neovascularization].
    Hattori Y
    Nihon Naika Gakkai Zasshi; 2002 Sep; 91 Suppl():121-6. PubMed ID: 12577958
    [No Abstract]   [Full Text] [Related]  

  • 2. [New observations support the significance of angiogenesis in myeloma].
    Lundberg LG; Lerner R; Palmblad J
    Lakartidningen; 2001 Nov; 98(45):4985-90. PubMed ID: 11816901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of thalidomide in the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 5. [Importance of thalidomide in the treatment of cancer].
    Bay JO; Tournilhac O
    Bull Cancer; 2000 Apr; 87(4):301-2. PubMed ID: 10858046
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent studies on the thalidomide and its derivatives.
    Łączkowski KZ; Baranowska-Łączkowska A
    Future Med Chem; 2018 Sep; 10(18):2133-2136. PubMed ID: 30088422
    [No Abstract]   [Full Text] [Related]  

  • 8. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
    Lacy MQ; Rajkumar SV
    Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
    [No Abstract]   [Full Text] [Related]  

  • 9. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thalidomide: (re)discovery of a not very dear old molecule].
    Bressoud A; Schwab BZ
    Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
    Ribatti D; Vacca A
    Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476
    [No Abstract]   [Full Text] [Related]  

  • 12. Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease.
    Candoni A; Simeone E; Fanin R
    Am J Hematol; 2008 Aug; 83(8):680-1. PubMed ID: 18459108
    [No Abstract]   [Full Text] [Related]  

  • 13. Unusual myeloma relapse after thalidomide therapy: the dark side of the moon?
    Balleari E; Bruzzone A
    Leuk Res; 2009 Sep; 33(9):1164-5. PubMed ID: 19446332
    [No Abstract]   [Full Text] [Related]  

  • 14. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
    Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
    Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
    [No Abstract]   [Full Text] [Related]  

  • 15. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide as anti-inflammatory therapy for multiple myeloma.
    Mehta P; Hussein M
    Leukemia; 2003 Nov; 17(11):2237-8; author reply 2238. PubMed ID: 12931217
    [No Abstract]   [Full Text] [Related]  

  • 18. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
    Hattori Y
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():596-600. PubMed ID: 17476758
    [No Abstract]   [Full Text] [Related]  

  • 20. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.